There are few pathological descriptions of the healing phase ... sequelae of respiratory distress syndrome described here also resemble, to a small extent, the findings in cystic fibrosis of ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...

TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...

The company intends to pursue an investigational new drug (IND) application for a Phase 2 study in moderate-to-severe ... funded platform study as a treatment for Acute Respiratory Distress Syndrome, ...

TDI01 is a novel and highly selective ROCK2 inhibitor that is currently being tested in phase I clinical trials for the treatment ... inflammation and vascular leakage in LPS-induced ALI/ARDS. In ...

They are observed in ARDS, are especially covering denuded basement membranes where pneumocytes are missing, and may be related to adverse outcome (56). Endocytosis of macromolecules can be mediated ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...